Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 12 patents granted in the last 365 days
CytomX Therapeutics Inc. has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 5 distinct examiners but only 2 distinct art units, indicating broad examiner distribution within a narrower set of technical examination groups.
NICKOL, GARY B is the busiest examiner with 1 pending action. Since no examiner controls a substantial share of the docket, counsel should manage responses at the application level and use the shared art-unit structure to monitor recurring issues.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (60%) |
| Double-patenting + other | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NICKOL, GARY B | 1 | 46.6% | +33.3% |
| STOICA, ELLY GERALD | 1 | 66.8% | +22.6% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| HAMA, JOANNE | 1 | 25.4% | +40.2% |
| BRISTOL, LYNN ANNE | 1 | 63.4% | +39.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17288469 | EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND USES THEREOF | HAMA, JOANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18701356 | ACTIVATABLE ANTI-CD3, ANTI-EGFR, HETEROMULTIMERIC BISPECIFIC POLYPEPTIDE COMPLEX | NICKOL, GARY B | — |
| 18400894 | MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF | STOICA, ELLY GERALD | — |
| 18354353 | ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF | CANELLA, KAREN A | — |
| 17288469 | EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND USES THEREOF | HAMA, JOANNE | — |
| 17230240 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME | BRISTOL, LYNN ANNE | — |
| Art Unit | Apps |
|---|---|
| 1647 | 2 |
| 1643 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18701356 | ACTIVATABLE ANTI-CD3, ANTI-EGFR, HETEROMULTIMERIC BISPECIFIC POLYPEPTIDE COMPLEX | NICKOL, GARY B | — | §112 | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18400894 | MODIFIED ANTIBODY COMPOSITIONS, METHODS OF MAKING AND USING THEREOF | STOICA, ELLY GERALD | 1647 | §112DP | Non-Final OA | — | Pending | Dec 29, 2023 |
| 18354353 | ANTI-CD166 ANTIBODIES, ACTIVATABLE ANTI-CD166 ANTIBODIES, AND METHODS OF USE THEREOF | CANELLA, KAREN A | 1643 | §112DP | Non-Final OA | — | Pending | Jul 18, 2023 |
| 17288469 | EPCAM ANTIBODIES, ACTIVATABLE ANTIBODIES, AND IMMUNOCONJUGATES, AND USES THEREOF | HAMA, JOANNE | 1647 | §112 | Non-Final OA | — | Pending | Apr 23, 2021 |
| 17230240 | MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USING THE SAME | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | — | Pending | Apr 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCytomX Therapeutics Inc. has 5 pending office actions as of October 2026, spread across 2 art units and 5 examiners.
Gary B Nickol has the most, with 1 of CytomX Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
